Boston Scientific Q2 2020 Earnings Report
Key Takeaways
Boston Scientific reported a decline in sales and a GAAP loss for the second quarter of 2020, primarily due to the impact of the COVID-19 pandemic. However, the company saw business recovering over the course of the quarter and achieved adjusted earnings per share of $0.08.
Second quarter sales declined in each reportable segment compared to the prior year period.
Second quarter regional sales also declined compared to the prior year period.
Received FDA approval for the WATCHMAN FLXâ„¢ Left Atrial Appendage Closure (LAAC) Device.
Launched a multi-year program to combat racism, inequity and injustice, including $3.5 million in philanthropic commitments.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Forward Guidance
The company did not provide second quarter sales and EPS guidance due to ongoing uncertainty associated with the scope and duration of the COVID-19 pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income